Evidence that phospholipid oxidation products and/or platelet-activating factor play an important role in early atherogenesis: In vitro and in vivo inhibition by WEB 2086

Circulation Research

Volumn 85, Issue 4, 1999, Pages 311-318

  Subbanagounder, Ganesamoorthy ^a,b   Leitinger, Norbert ^a   Shih, Peggy T ^a   Faull, Kym F ^a   Berliner, Judith A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Oxidized phospholipid; Platelet activating factor; Platelet activating factor like lipid; WEB 2086

Indexed keywords

APAFANT; PHOSPHORYLCHOLINE; THROMBOCYTE ACTIVATING FACTOR;

ANIMAL CELL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL ACTIVATION; CELL INTERACTION; ENDOTHELIUM CELL; LEUKOCYTE ACTIVATION; LIPID OXIDATION; MONOCYTE; NONHUMAN; PRIORITY JOURNAL;

EID: 0033588208     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.85.4.311     Document Type: Article

References (44)

1. Hara A, Taketomi T. Characterization and change of phospholipids in the aorta of Watanabe hereditable hyperlipidemic rabbit. Jpn J Exp Med. 1990;60:311-318.
2. Itabe H, Takeshima E, Iwasaki H, Kimura J, Yoshida Y, Imanaka T, Takano T. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides. J Biol Chem. 1994;269: 15274-15279.
3. Palinski W, Hörkkö S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK, Witztum JL. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest. 1996;98:800-814.
4. Watson AD, Leitinger N, Navab M, Faull KF, Hörkkö S, Witztum JL, Palinski W, Schwenke D, Salomon RG, Sha W, Subbanagounder G, Fogelman AM, Berliner JA. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem. 1997;272:13597-13607.
5. Watson AD, Subbanagounder G, Welsbie DS, Faull KF, Navab M, Jung ME, Fogelman AM, Berliner JA. Structural identification of a novel pro-inflammatory epoxy isoprostane phospholipid in minimally oxidized low density lipoprotein. J Biol Chem. In press.
6. Mueller HW, Haught CA, McNatt JM, Cui K, Gaskell SJ, Johnston DA, Willerson JT. Measurement of platelet-activating factor in a canine model coronary thrombosis and in endarterectomy samples from patients with advanced coronary artery disease. Circ Res. 1995;71:54-63.
7. Tokumura A, Toujima M, Yoshioka Y, Fukuzawa K. Lipid peroxidation in low density lipoproteins from human plasma and egg yolk promotes accumulation of 1-acyl analogues of platelet-activating factor-like lipids. Lipids. 1996;31:1251-1258.
8. Heery JM, Kozak M, Stafforini DM, Jones DA, Zimmerman GA, McIntyre TM, Prescott SM. Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. J Clin Invest. 1995;96:2322-2330.
9. Marthe G, Davies SS, Harrison KA, Murphy RC, Zimmerman GA, Prescott SM, McIntyre TM. Platelet activating factor-like proinflammatory lipids in oxidatively modified human LDL. Presented at the Sixth International Congress on Platelet-Activating Factor and Related Lipid Mediators; September 21-24, 1998; New Orleans, La. Abstract 74.
10. Zimmerman GA, Prescott SM, McIntyre TM. Oxidatively fragmented phospholipids as inflammatory mediators: the dark side of polyunsaturated lipids. J Nutr. 1995;125:1661S-1665S.
11. Smiley PL, Slremler KE, Prescott SM, Zimmerman GA, McIntyre TM. Oxidatively fragmented phosphatidylcholines activate human neutrophils through the receptor for platelet-activating factor. J Biol Chem. 1991; 266:11104-11110.
12. Le Blanc K, Samuelsson J, Brohult J, Berg A, Palmblad J. 1-O-hexadecyl-2-methoxy-glycero-3-phosphatidylcholine-a methoxy ether lipid inhibiting platelet activating factor-induced platelet aggregation and neutrophil oxidative metabolism. Biochem Pharmacol. 1995;49: 1577-1582.
13. Tanaka T, Iimori M, Tsukalani H, Tokumura A. Platelet-aggregating effects of platelet-activating factor-like phospholipids formed by oxidation of phosphatidylcholines containing an sn-2-polyunsaturated fatty acyl group. Biochim Biophys Acta. 1994;1210:202-208.
14. Imaizumi T-A, Satoh K, Yoshida H, Kawamura Y, Hiramoto M, Takamatsu S. Effect of cigarette smoking on the levels of platelet activating factor-like lipids in plasma lipoproteins. Atherosclerosis. 1991;87: 47-55.
15. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med. 1996;20:707-727.
16. Berliner JA, Leitinger N, Watson AD, Huber J, Fogelman AM, Navab M. Oxidized lipids in atherogenesis: formation, destruction and action. Thromb Haemost. 1997;78:195-199.
17. 3) is implicated, in cooperation with P-selectin and platelet-activating factor, in the adhesion of monocytes to activated endothelial cells. Biochem J. 1994;304: 537-542.
18. Shen Y, Sultana C, Arditi M, Kim KS, Kalra VK. Endotoxin-induced migration of monocytes and PECAM-1 phosphorylation are abrogated by PAF receptor antagonists. Am J Physiol. 1998;275:E479-E486.
19. Zimmerman GA, Elstad MR, Lorant DE, McIntyre TM, Prescott SM, Topham MK, Weyrich AS, Whatley RE. Platelet-activating factor (PAF): signaling and adhesion in cell-cell interactions. Adv Exp Med Biol. 1996; 416:297-304.
20. Patel KD, Zimmerman GA, Prescott SM, McIntyre TM. Novel leukocyte agonists are released by endothelial cells exposed to peroxide. J Biol Chem. 1992;267:15168-15175.
21. Khan BV, Parthasarathy SS, Alexander RW, Medford RM. Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest. 1995;95:1262-1270.
22. Lehr H-A, Weyrich AS, Saetzler RK, Jurek A, Arfors KE, Zimmerman GA, Prescott SM, McIntyre TM. Vitamin C blocks inflammatory platelet-activating factor mimetics created by cigarette smoking. J Clin Invest. 1997;99:2358-2364.
23. Lehr H-A, Seemüller J, Hübner C, Menger MD, Messmer K. Oxidized LDL-induced leukocyte/endothelium interaction in vivo involves the receptor for platelet-activating factor. Arterioscler Thromb. 1993;13: 1013-1018.
24. Leitinger N, Watson AD, Faull KF, Fogelman AM, Berliner JA. Monocyte binding to endothelial cells induced by oxidized phospholipids present in minimally oxidized low density lipoprotein is inhibited by a platelet activating factor receptor antagonist. Adv Exp Med Biol. 1997; 433:379-382.
25. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Bamshad B, Esterson M, Fogelman AM. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest. 1990;85: 1260-1266.
26. Fogelman AM, Sykes K, Van Lenten BJ, Territo MC, Berliner JA. Modification of the Recalde method for the isolation of human monocytes. J Lipid Res. 1988;29:1243-1247.
27. Qiao JH, Xie PZ, Fishbein MC, Kreuzer J, Drake TA, Demer LL, Lusis AJ. Pathology of atheromatous lesions in inbred and genetically engineered mice. Genetic determination of arterial calcification. Arterioscler Thromb. 1994;14:1480-1497.
28. Shih PT, Brennan M-L, Vora DK, Territo MC, Strahl D, Elices MJ, Lusis AJ, Berliner JA. Blocking very late antigen-4 integrin decreases leukocyte entry and fatty streak formation in mice fed an atherogenic diet. Circ Res. 1999;84:345-351.
29. Mehrabian M, Qiao JH, Hyman R, Ruddle D, Laughton C, Lusis AJ. Influence of the apoA-II gene locus on HDL levels and fatty streak development in mice. Arterioscler Thromb. 1993;13:1-10.
30. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 1957; 226:497-509.
31. Han X, Gubitosi-Klug RA, Collins BJ, Gross RW. Alterations in individual molecular species of human platelet phospholipids during thrombin stimulation: electrospray ionization mass spectrometry-facilitated identification of the boundary conditions for the magnitude and selectivity of thrombin-induced platelet phospholipid hydrolysis. Biochemistry. 1996;35:5822-5832.
32. Hu W, McNicholl IK, Choy PC, Man RY. Partial agonist effect of the platelet-activating factor receptor antagonists, WEB 2086 and WEB 2170, in the rat perfused heart. Br J Pharmacol. 1993;110:645-650.
33. Berliner JA, Leitinger N, Subbanagounder G, Tyner T, Watson AD. Regulation of leukocyte adhesion to the endothelium by oxidized phospholipids. Presented at the Sixth International Congress on Platelet-Activating Factor and Related Lipid Mediators; September 21-24, 1998; New Orleans, La. Abstract 28.
34. Predescu D, Ihida K, Predescu S, Palade GE. The vascular distribution of the platelet-activating factor receptor. Eur J Cell Biol. 1996;69:86-98.
35. Kem H, Volk T, Knauer-Schiefer S, Mieth T, Rüstow B, Kox WJ, Schlame M. Stimulation of monocytes and platelets by short chain phosphatidylcholines with and without terminal carboxyl group. Biochim Biophys Acta. 1998;1394:33-42.
36. O'Flaherty J, Tessner T, Greene D, Redman JR, Wykle RL. Comparison of 1-O-alkyl-, 1-O-alk-1′-enyl-, and 1-O-acyl-2-acetyl-sn-glycero-3-phosphoethanolamines and -3-phosphocholines as agonists of the platelet-activating factor family. Biochim Biophys Acta. 1994;1394:209-216.
37. Casals-Stenzal J, Muacevic G, Weber KH. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor. J Pharmacol Exp Ther. 1987;241:974-981.
38. Stremler KE, Stafforini DM, Prescott SM, Zimmerman GA, McIntyre TM. An oxidized derivative of phosphatidylcholine is a substrate for the platelet-activating factor acetylhydrolase from human plasma. J Biol Chem. 1989;264:5331-5334.
39. Stafforini DM, Prescott SM, Zimmerman GA, McIntyre TM. Platelet-activating factor acetylhydrolase activity in human tissues and blood cells. Lipids. 1991;26:979-985.
40. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995;96:2882-2891.
41. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, McIntyre TM, La Du BN, Fogelman AM, Berliner JA. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest. 1995;95: 774-782.
42. Prescott SM, Wither PAF. Presented at the Sixth International Congress on Platelet-Activating Factor and Related Lipid Mediators; September 21-24, 1998; New Orleans, La. Abstract 3.
43. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394:284-287.
44. Hörkkö S, Bird DA, Miller E, Itabe H, Leitinger N, Subbanagounder G, Berliner JA, Friedman P, Dennis EA, Curtis LK, Palinski W, Witztum JL. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophages uptake of oxidized low-density lipoproteins. J Clin Invest. 1999;103:117-128.